IXHLNasdaq

Incannex Healthcare Inc.

Healthcare·Neurology·Phase 2·Sydney, NSW, Australia
NeurologyImmunologyRespiratoryPainMusculoskeletalPsychiatry

Incannex Healthcare Inc. (IXHL): 4 pipeline candidates · 1 upcoming catalyst · ~93 mo cash runway · 3 clinical trials. Updated within the last hour.

7.7/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway10.0

93.0 months

Financial Health9.9

D/E 0.07 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 2/Phase 3

Pipeline Breadth7.2

4 candidates

Catalyst Momentum3.0

1 upcoming, next in ~166d

Insider SignalN/A

N/A

A transparent, data-derived signal for Incannex Healthcare Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$43.9M

Cash

$74.5M

Quarterly Burn

$2.5M

Runway

93.0 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Mar 2034
Today~102 mo out
Catalyst within runway

Pipeline (4 candidates)

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

14

Total value held

$1.1M

HolderSharesValue
ghisallo capital management llc162,855$489K
mirae asset global etfs holdings ltd.149,857$450K
advisorshares investments llc24,503$74K
commonwealth equity services, llc12,112$36K
osaic holdings, inc.6,376$19K
morgan stanley2,065$6K
quent capital, llc1,928$6K
jpmorgan chase & co825$3K
barclays plc750$2K
larson financial group llc59$177

Showing top 10 of 14 institutional holders of Incannex Healthcare Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

3 clinical trials·CEO: Mr. Joel Bradley Latham

Frequently asked questions

How many drug candidates are in Incannex Healthcare Inc.'s pipeline?

Incannex Healthcare Inc. (IXHL) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Incannex Healthcare Inc.'s lead drug candidate?

Incannex Healthcare Inc.'s most advanced tracked candidate is hydroxychloroquine (Phase 2) for Rheumatoid Arthritis.

What is Incannex Healthcare Inc.'s next catalyst?

Incannex Healthcare Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase II/III, Randomised, Double-Blind Clinical Trial to Determine the Safety and Efficacy of IHL-" — expected December 1, 2026.

What is Incannex Healthcare Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Incannex Healthcare Inc. has approximately 93.0 months of cash runway.

What is Incannex Healthcare Inc.'s market capitalization?

Incannex Healthcare Inc.'s market capitalization is approximately $43.9M.

Get the full picture on Incannex Healthcare Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.